| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-08 |
| mRNA | TG-101348 | GDSC1000 | pan-cancer | AAC | 0.16 | 1e-07 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.28 | 2e-07 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-07 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-07 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.18 | 6e-07 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 7e-07 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.26 | 1e-06 |